Comparing Atezolizumab With or Without Radiation Therapy for Extensive Stage Small Cell Lung Cancer A Randomized Phase IIIII Study

What this Trial Is About

This trial studies patients with extensive stage small cell lung cancer that has spread outside the lung. It compares the effects of adding radiation therapy to the usual maintenance treatment with atezolizumab versus using atezolizumab alone. Researchers aim to see if combining radiation with immunotherapy can extend the time before the cancer grows or spreads, and improve overall survival. The study is a phase IIIII randomized trial sponsored by the National Cancer Institute. Participants are randomly assigned to one of two groups. One group receives atezolizumab intravenously every 21 days. The other group receives the same atezolizumab treatment plus radiation therapy once daily on days 1 through 5 during the first five weeks. Both groups undergo imaging scans including PETCT, CT, and MRI, as well as blood and tissue collections during the trial. Throughout the study, participants are monitored closely with scans and lab tests. After treatment ends, follow-up visits occur every 3 months for 2 years, then every 6 months for 3 years, and annually thereafter. Researchers measure progression-free survival and overall survival up to 6 years, along with side effects and how tumor characteristics may affect outcomes. The trial evaluates the benefits and risks of combining radiation with atezolizumab for this cancer.

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial